AstraZeneca Q3 Sales Rise 'Is Milestone', CEO Soriot 'Not Leaving'
Executive Summary
AstraZeneca's third-quarter results show it has emerged from a long decline and returned to growth, fuelled by new products and pipeline, the UK pharma's CEO Pascal Soriot told reporters, adding that he's having too much fun turning the group around to leave any time soon.
You may also be interested in...
AstraZeneca Rejig Brings Baselga On Board
A reorganization at the top of the UK firm brings with it controversial scientist Jose Baselga.
R&D Heads At GSK & AZ Say Key To Success Lies In Smart Risk Taking
AZ's Mene Pangalos and GSK's Hal Barron are at different stages of overseeing culture changes in their respective R&D workforces - but both agreed at a recent conference that such transformations are key for the future viability of their drug companies.
AstraZeneca: DECLARE-TIMI Outcomes May Support Competitive Claim For Farxiga In Heart Failure
Lack of significant reduction on cardiovascular deaths or a composite of major events may have been due to enrollment of a healthier population relative to other studies, said investigators from the DECLARE-TIMI 58 outcomes study, which was reported at the AHA meeting.